Jillian D Cavanaugh
Overview
Explore the profile of Jillian D Cavanaugh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kitajima S, Asahina H, Chen T, Guo S, Quiceno L, Cavanaugh J, et al.
Cancer Cell
. 2018 Sep;
34(3):439-452.e6.
PMID: 30205046
Despite extensive efforts, oncogenic KRAS remains resistant to targeted therapy. Combined downstream RAL-TBK1 and MEK inhibition induces only transient lung tumor shrinkage in KRAS-driven genetically engineered mouse models (GEMMs). Using...
2.
Akbay E, Koyama S, Liu Y, Dries R, Bufe L, Silkes M, et al.
J Thorac Oncol
. 2017 May;
12(8):1268-1279.
PMID: 28483607
Introduction: Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a protumorigenic inflammatory phenotype and inhibits antitumor immune responses. Methods:...
3.
Herter-Sprie G, Koyama S, Korideck H, Hai J, Deng J, Li Y, et al.
JCI Insight
. 2016 Oct;
1(9):e87415.
PMID: 27699275
Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However, despite initial tumor control, most patients suffer from...
4.
Koyama S, Akbay E, Li Y, Aref A, Skoulidis F, Herter-Sprie G, et al.
Cancer Res
. 2016 Feb;
76(5):999-1008.
PMID: 26833127
STK11/LKB1 is among the most commonly inactivated tumor suppressors in non-small cell lung cancer (NSCLC), especially in tumors harboring KRAS mutations. Many oncogenes promote immune escape, undermining the effectiveness of...
5.
Christensen C, Kwiatkowski N, Abraham B, Carretero J, Al-Shahrour F, Zhang T, et al.
Cancer Cell
. 2014 Dec;
26(6):909-922.
PMID: 25490451
Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC biology represents an urgent need. Using a high-throughput...